It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!
Patients with heart failure and reduced ejection fraction (HF-REF) treated with an investigational angiotensin receptor neprilysin Inhibitor (ARNI) are more likely to reduce cardiovascular death and heart failure hospitalization than...
Teens who received the collaborative care intervention in primary care had significantly greater improvements in depressive symptoms than teens who were receiving treatment as usual.

LATEST
Ibuprofen safe, effective in ...

In children discharged home with a fracture, both ibuprofen and oral morphine were effective at relieving pain. However, ...

FDA: Limit use of anticoagulant edoxaban
[BLOG]: How to position your ...
[BLOG]: Emerging targets in ...
Ebola clinical activity heats up ...

FDA APPROVALS
FDA approves first vaccine for ...

Meningococcal group B vaccine (Trumenba, Pfizer) has been granted accelerated approval by FDA as the first vaccine ...

New antiarrhythmic agent gets FDA ...
FDA approves Obizur for acquired ...
FDA approves abuse-deterrent ...

CLINICAL
FDA: Limit use of anticoagulant edoxaban

FDA advisors have recommended approval of a 60-mg dose of edoxaban (Daiichi Sankyo), a once-daily anticoagulant that ...

FDA approves first vaccine for ...
Ibuprofen safe, effective in ...
New antiarrhythmic agent gets FDA ...

DRUGS IN PERSPECTIVE
Drug Overview: Zykadia (ceritinib)

Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the ...

Drugs in Perspective: Dalvance
Drug Overview: Tasimelteon (Hetlioz)
Drug Overview: Aptiom ...

Latest Tweets Follow